Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous sarilumab plus standard of care vs standard of care in severe COVID-19 pneumonia (phase 3)
2020-001390-76Phase 3Completed
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19), viral pneumonia and Viral lower respiratory tract infection (VLRTI) comparing Sarilumab + standard of care with Standard of care alone (2 arms). Primary endpoint: Time to clinical improvement. Started Jun 2020; status: completed.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumoniaViral lower respiratory tract infection (VLRTI)
Beyond the preview
Go deeper on 2020-001390-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001390-76.